TY - JOUR AU - Rembeck, Karolina AU - Maglio, Cristina AU - Lagging, Martin AU - Christensen, Peer Brehm AU - Färkkilä, Martti AU - Langeland, Nina AU - Buhl, Mads Rauning AU - Pedersen, Court AU - Mørch, Kristine AU - Norkrans, Gunnar AU - Hellstrand, Kristoffer AU - Lindh, Magnus AU - Pirazzi, Carlo AU - Burza, Maria Antonella AU - Romeo, Stefano AU - Westin, Johan AU - for the NORDynamIC group PY - 2012 DA - 2012/09/14 TI - PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection JO - BMC Medical Genetics SP - 82 VL - 13 IS - 1 AB - Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients. SN - 1471-2350 UR - https://doi.org/10.1186/1471-2350-13-82 DO - 10.1186/1471-2350-13-82 ID - Rembeck2012 ER -